Literature DB >> 24678732

Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex.

Jason P Garee1, Christopher D Chien, Jordan V Li, Anton Wellstein, Anna T Riegel.   

Abstract

Transcription of the HER2 oncogene can be repressed by estrogen (E2). We now show that, a splice isoform of the nuclear receptor coactivator AIB1, AIB1-Δ4, is able to reverse E2 repression of HER2 gene expression in breast cancer cells. The first 224 amino acids of AIB1 that are absent in AIB1-Δ4, bind a co-repressor, ANCO1. Using chromatin immunoprecipitation assay approaches in MCF7 and BT474 cell lines, we demonstrate that AIB1 and AIB1-Δ4 can bind to the E2 regulatory site in the first intron of the HER2 gene, after E2 treatment, but only full-length AIB1 recruits ANCO1. Consistent with E2-induced chromatin repression, the AIB1-ANCO1 complex recruits HDAC3 and HDAC4 to the intronic estrogen response element and the proximal promoter acquires the repressive chromatin mark H3K9me3 and loses H3K4me1. In contrast, AIB1-Δ4 does not recruit ANCO 1, HDAC3, or HDAC4 and the proximal promoter retains activation marks of H3K4me1. In cell lines with low levels of ANCO1 (T47D), E2 does not repress HER2 gene transcription but the repressive response can be restored by overexpression of ANCO1. ANCO1 can also repress other E2-responsive genes, indicating that AIB1, AIB1-Δ4 and ANCO1 are important determinants of endocrine and growth factor responsiveness in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24678732      PMCID: PMC4042073          DOI: 10.1210/me.2013-1379

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  37 in total

1.  Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators.

Authors:  Aihua Zhang; Percy Luk Yeung; Chia-Wei Li; Shih-Chieh Tsai; Gia Khanh Dinh; Xiaoyang Wu; Hui Li; J Don Chen
Journal:  J Biol Chem       Date:  2004-06-07       Impact factor: 5.157

2.  A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome.

Authors:  Luigi Cicatiello; Claudio Scafoglio; Lucia Altucci; Massimo Cancemi; Guido Natoli; Angelo Facchiano; Giovanni Iazzetti; Raffaele Calogero; Nicoletta Biglia; Michele De Bortoli; Christian Sfiligoi; Piero Sismondi; Francesco Bresciani; Alessandro Weisz
Journal:  J Mol Endocrinol       Date:  2004-06       Impact factor: 5.098

3.  An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer.

Authors:  R Reiter; A Wellstein; A T Riegel
Journal:  J Biol Chem       Date:  2001-08-13       Impact factor: 5.157

4.  Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer.

Authors:  S P Newman; N P Bates; D Vernimmen; M G Parker; H C Hurst
Journal:  Oncogene       Date:  2000-01-27       Impact factor: 9.867

5.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Authors:  C Kent Osborne; Valerie Bardou; Torsten A Hopp; Gary C Chamness; Susan G Hilsenbeck; Suzanne A W Fuqua; Jiemin Wong; D Craig Allred; Gary M Clark; Rachel Schiff
Journal:  J Natl Cancer Inst       Date:  2003-03-05       Impact factor: 13.506

6.  High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.

Authors:  Maria I Torres-Arzayus; Jaime Font de Mora; Jing Yuan; Francisca Vazquez; Roderick Bronson; Montserrat Rue; William R Sellers; Myles Brown
Journal:  Cancer Cell       Date:  2004-09       Impact factor: 31.743

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.

Authors:  K B Horwitz; Y Koseki; W L McGuire
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

9.  Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.

Authors:  Ronald Reiter; Annabell S Oh; Anton Wellstein; Anna Tate Riegel
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

10.  The 5' flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein.

Authors:  A M Nunez; M Berry; J L Imler; P Chambon
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

View more
  6 in total

1.  One repressor to rule them all: ANCO1 links YAP and AIB1.

Authors:  Can Zhang; Kenneth Moberg
Journal:  EMBO Rep       Date:  2019-12-02       Impact factor: 8.807

2.  Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.

Authors:  Noura Al-Zeheimi; Sirin A Adham
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

3.  Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.

Authors:  Damir Varešlija; Elspeth Ward; Siobhan P Purcell; Nicola S Cosgrove; Sinéad Cocchiglia; Philip J O'Halloran; Sara Charmsaz; Fiona T Bane; Francesca M Brett; Michael Farrell; Jane Cryan; Alan Beausang; Lance Hudson; Arran K Turnbul; J Michael Dixon; Arnold D K Hill; Nolan Priedigkeit; Steffi Oesterreich; Adrian V Lee; Andrew H Sims; Aisling M Redmond; Jason S Carroll; Leonie S Young
Journal:  Oncogene       Date:  2021-01-08       Impact factor: 9.867

4.  AIB1 is a novel target of the high-risk HPV E6 protein and a biomarker of cervical cancer progression.

Authors:  Jonathan Miller; Aleksandra Dakic; Megan Spurgeon; Francisco Saenz; Bhaskar Kallakury; Bo Zhao; Junran Zhang; Jian Zhu; Qin Ma; Ying Xu; Paul Lambert; Richard Schlegel; Anna T Riegel; Xuefeng Liu
Journal:  J Med Virol       Date:  2022-04-27       Impact factor: 20.693

5.  Loss of ANCO1 repression at AIB1/YAP targets drives breast cancer progression.

Authors:  Max H Kushner; Virginie Ory; Garrett T Graham; Ghada M Sharif; William B Kietzman; Sophia Thevissen; Meng Yuan; Marcel O Schmidt; Anton Wellstein; Anna T Riegel
Journal:  EMBO Rep       Date:  2019-12-02       Impact factor: 8.807

6.  An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer.

Authors:  Ghada M Sharif; Moray J Campbell; Apsra Nasir; Surojeet Sengupta; Garrett T Graham; Max H Kushner; William B Kietzman; Marcel O Schmidt; Gray W Pearson; Olivier Loudig; Susan Fineberg; Anton Wellstein; Anna T Riegel
Journal:  Cancer Res       Date:  2021-06-16       Impact factor: 12.701

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.